Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -58.10% is 124% below its 5-year average of -25.91%, near the low end of its 5-year range (-58.10%–-4.46%).
56.69% below its 12-month average of -37.08%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.33%.
RETURN ON ASSETS (ROA)
-58.10%
RETURN ON ASSETS (ROA) AVG TTM
-37.08%
RETURN ON ASSETS (ROA) AVG 3Y
-28.02%
RETURN ON ASSETS (ROA) AVG 5Y
-25.91%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-56.69%
CURRENT VS 3Y AVG
-107.39%
CURRENT VS 5Y AVG
-124.21%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.55%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-146.66%
vs the sector median at left
Alector, Inc.
Market Cap
$220.94M
Return on Assets (ROA)
-58.10%
TTM Avg
-37.08%
3Y Avg
-28.02%
5Y Avg
-25.91%
Market Cap
$218.42M
Return on Assets (ROA)
25.43%
TTM Avg
5.08%
3Y Avg
-10.27%
5Y Avg
-14.74%
Market Cap
$206.61M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$236.56M
Return on Assets (ROA)
-29.12%
TTM Avg
-42.23%
3Y Avg
-51.88%
5Y Avg
-48.35%
Market Cap
$239.45M
Return on Assets (ROA)
-23.80%
TTM Avg
-23.59%
3Y Avg
-108.30%
5Y Avg
-108.30%
Market Cap
$202.05M
Return on Assets (ROA)
-44.41%
TTM Avg
-56.25%
3Y Avg
-49.77%
5Y Avg
-92.23%
Market Cap
$244.25M
Return on Assets (ROA)
-8.48%
TTM Avg
-16.43%
3Y Avg
-20.20%
5Y Avg
-32.31%
Market Cap
$245.65M
Return on Assets (ROA)
-187.80%
TTM Avg
-213.40%
3Y Avg
-188.65%
5Y Avg
-151.14%
Market Cap
$248.21M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alector, Inc. (ALEC) | $220.94M | -58.10% | -37.08% | -28.02% | -25.91% |
| Compugen Ltd. (CGEN)vs › | $218.42M | 25.43% | 5.08% | -10.27% | -14.74% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $236.56M | -29.12% | -42.23% | -51.88% | -48.35% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -23.80% | -23.59% | -108.30% | -108.30% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | -44.41% | -56.25% | -49.77% | -92.23% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | -8.48% | -16.43% | -20.20% | -32.31% |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | -187.80% | -213.40% | -188.65% | -151.14% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | -244.25% | -369.36% | -230.97% | -157.86% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -78.16% | -23.70% | -68.26% | -50.80% |
ROA
-58.1%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -48.74% |
| 2024-12-31 | -25.42% |
| 2023-12-31 | -20.97% |
| 2022-12-31 | -16.93% |
| 2021-12-31 | -4.46% |
| 2020-12-31 | -38.96% |
| 2019-12-31 | -24.98% |
| 2018-12-31 | -16.94% |
| 2017-12-31 | -13.76% |
| 2016-12-31 | -27.92% |
